Spero Therapeutics
SPRO
56 hedge funds and large institutions have $20.8M invested in Spero Therapeutics in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
17% more funds holding
Funds holding: 48 → 56 (+8)
1% more capital invested
Capital invested by funds: $20.6M → $20.8M (+$224K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.2% less ownership
Funds ownership: 27.52% → 27.32% (-0.2%)
15% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 13
86% less call options, than puts
Call options by funds: $26K | Put options by funds: $180K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$801K |
| 2 |
Renaissance Technologies
New York
|
+$313K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$297K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$171K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$171K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$1.57M |
| 2 |
Millennium Management
New York
|
-$207K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$93.4K |
| 4 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$73.5K |
| 5 |
AVAI
Atlas Venture Associates IX
Boston,
Massachusetts
|
-$40.5K |
SPRO Hedge Fund Activity: Q2 2023 in Review
56 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2023, worth a combined $20.8M — up 1.1% from $20.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new SPRO positions and 3 closed out — a net gain of 8 holders — while 11 added to existing stakes and 13 trimmed.
The largest buyer was Ameriprise, opening a new position worth an estimated $801K. The largest seller was AWM Investment Company, cutting an estimated $1.57M.
- 56 institutional investors held Spero Therapeutics (SPRO) as of Q2 2023, up from 48 in Q1 2023.
- Funds reported $20.8M of Spero Therapeutics stock for Q2 2023, up 1.1% quarter-over-quarter.
- 11 funds opened new Spero Therapeutics positions in Q2 2023 and 3 closed out, a net change of +8 holders.
- The largest Spero Therapeutics buyer in Q2 2023 was Ameriprise, an estimated $801K added.
- The largest Spero Therapeutics seller in Q2 2023 was AWM Investment Company, an estimated $1.57M sold.
Based on aggregated 13F filings for Q2 2023.